ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,174Medicare Part D Prescriptions Filled, Including Refills

Rank: 222 out of 973

$481K Total Retail Price of All Prescriptions

Rank: 159 out of 973

437 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
15% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Kansas
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 437 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

15% of this provider’s 437 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 7,236 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Kansas
SIMVASTATIN 498 439 1 1
LEVOTHYROXINE SODIUM 429 397 2 2
HYDROCODONE-ACETAMINOPHEN 371 308 S3 3 4
OMEPRAZOLE 219 185 4 5
LISINOPRIL 211 195 5 3
ATENOLOL 202 195 6 16
WARFARIN SODIUM 200 172 7 10
ZOLPIDEM TARTRATE 169 152 8 20
AMLODIPINE BESYLATE 169 150 8 7
METFORMIN HCL 137 116 10 8
HYDROCHLOROTHIAZIDE 123 106 11 11
FUROSEMIDE 120 116 12 6
TAMSULOSIN HCL 118 111 13 28
POTASSIUM CHLORIDE 113 108 14 9
MELOXICAM 107 101 15 23
LOSARTAN-HYDROCHLOROTHIAZIDE 106 97 16 46
ALENDRONATE SODIUM 105 85 17 24
GABAPENTIN 101 83 18 12
LOSARTAN POTASSIUM 101 74 18 19
METOPROLOL SUCCINATE 97 71 20 17
ATORVASTATIN CALCIUM 95 92 21 15
METHYLPREDNISOLONE 90 76 22 159
NAMENDA 86 77 23 31
SYNTHROID 83 83 24 50
AMLODIPINE BESYLATE-BENAZEPRIL 82 76 25 80
FLUOXETINE HCL 81 70 26 56
EVISTA 81 81 26 121
LISINOPRIL-HYDROCHLOROTHIAZIDE 79 55 28 25
CITALOPRAM HBR 76 66 29 14
PANTOPRAZOLE SODIUM 68 45 30 37
TRIAMTERENE-HCTZ 67 59 31 51
METOPROLOL TARTRATE 59 47 32 13
DIOVAN HCT 59 51 32 145
BENAZEPRIL HCL 56 53 34 62
CLINDAMYCIN HCL 56 48 34 355
DONEPEZIL HCL 55 45 36 26
DIOVAN 53 53 37 63
AZITHROMYCIN 53 46 37 47
LOVASTATIN 52 52 39 38
FENOFIBRATE 52 52 39 77
TRAZODONE HCL 51 40 41 48
ENALAPRIL MALEATE 50 50 42 55
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 16, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.